山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (10): 3-8.doi: 10.6040/j.issn.1671-7554.0.2018.1028
• • 上一篇
中国医师协会检验医师分会妇科肿瘤检验医学专家委员会
中图分类号:
| [1] Collins Y, Holcomb K, Chapman-Davis E, et al. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology[J]. Gynecol Oncol, 2014, 133(2): 353-361. [2] Bourla AB, Zamarin D. Immunotherapy: new strategies for the treatment of gynecologic malignancies[J]. Oncology(Williston Park), 2016, 30(1): 59-66, 69. [3] Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer[J]. Clin Chim Acta, 2013, 415: 341-345. doi: 10.1016/j.cca.2012.10.058. [4] 邹瑟音,夏勇,梁思宇,等. 联合检测肿瘤标志物在卵巢癌诊断中的临床应用评价[J].检验医学与临床, 2014, 11(23): 3316-3317. [5] 张宏兴. 血清CA125, CA199, CEA, AFP联监在卵巢癌诊断中应用价值研究[J].中国妇幼保健,2013, 25(3):4247-4249. ZHANG Hongxing. Study on application value of joint detection of serum CA125, CA19-9, CEA, and AFP in diagnosis of ovarian cancer [J]. Maternal and Child Health Care of China, 2013, 25(3): 4247-4249. [6] Rein BJ, Gupta S, Dada R, et al. Potential markers for detection and monitoring of ovarian cancer[J]. J Oncol, 2011, 2011: 475983. doi: 10.1155/2011/475983. [7] Buamah P. Benign conditions associated with raised serum CA-125 concentration[J]. J Surg Oncol, 2000, 75(4): 264-265. [8] Buamah PK, Skillen AW. Serum CA 125 concentrations in patients with benign ovarian tumours[J]. J Surg Oncol, 1994, 56(2): 71-74. [9] Niloff JM, Klug TL, Schaetzl E, et al. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix[J]. Am J Obstet Gynecol, 1984, 148(8): 1057-1058. [10] Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer[J]. Clin Chim Acta, 2013, 415: 341-345. doi: 10.1016/j.cca.2012.10.058. [11] Tate S, Hirai Y, Takeshima N, et al. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma[J]. Gynecol Oncol, 2005, 96(1): 143-149. [12] Le T, Faught W, Hopkins L, et al. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer[J]. J Obstet Gynaecol Can, 2008, 30(8): 665-670. [13] Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40[J]. J Clin Oncol, 2004, 22(16): 3330-3339. [14] Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range[J]. J Clin Oncol, 2005, 23(36): 9338-9343. [15] Rustin GJ, Nelstrop AE, Mcclean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125[J]. J Clin Oncol, 1996, 14(5): 1545-1551. [16] Kirchhoff C. Molecular characterization of epididymal proteins[J]. Rev Reprod, 1998, 3(2): 86-95. [17] Montagnana M, Danese E, Giudici S, et al. HE4 in ovarian cancer: from discovery to clinical application[J]. Adv Clin Chem, 2011, 55: 1-20. [18] Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008, 108(2): 402-408. [19] Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J]. Gynecol Oncol, 2008, 110(3): 374-382. [20] Drapkin R, Von Horsten HH, Lin Y, et al. Human epididymis protein 4(HE4)is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J]. Cancer Res, 2005, 65(6): 2162-2169. [21] Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?[J]. Arch Gynecol Obstet, 2013, 288(1): 167-172. [22] Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass[J]. Am. J Obstet Gynecol, 2010, 203(3): 228.e1-228.e6. doi: 10.1016/j.ajog.2010.03.043. [23] Tian, Y, Wang C, Cheng L, et al. Determination of reference intervals of serum levels of human epididymis protein 4(HE4)in Chinese women [J] J Ovarian Res, 2015. 8(1): 72. [24] Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer[J]. JAMA, 2002, 287(13): 1671-1679. [25] Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer[J]. J Clin Oncol, 2010, 28(13): 2159-2166. [26] Pal MK, Rashid M, Bisht M. Multiplexed magnetic nanoparticle-antibody conjugates(MNPs-ABS)based prognostic detection of ovarian cancer biomarkers, CA-125, beta-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance(SPR)analysis[J]. Biosens Bioelectron, 2015, 73: 146-152. doi: 10.1016/j.bios.2015.05.051. [27] Richardson MA. Complementary and alternative therapy use in gynecologic oncology: implications for clinical practice[J]. Gynecol Oncol, 2002, 84(3): 360-362. [28] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [29] Du PL, Wu KS, Fang JY, et al. Cervical Cancer Mortality Trends in China, 1991-2013, and Predictions for the Future[J]. Asian Pac J Cancer Prev, 2015, 16(15): 6391-6396. [30] Ohara K, Tanaka Y, Tsunoda H, et al. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging[J]. Obstet Gynecol, 2002, 100(4): 781-787. [31] Takeda M, Sakuragi N, Okamoto K, et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix[J]. Acta Obstet Gynecol Scand, 2002, 81(5): 451-457. [32] Gaarenstroom KN, Kenter GG, Bonfrer JM, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?[J]. Gynecol Oncol, 2000, 77(1): 164-170. [33] Chou CY, Wang ST, Kuo HC, et al. Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer[J]. Cancer, 1994, 74(9): 2497-2501. [34] Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix[J]. Gynecol Oncol, 1994, 55(2): 169-173. [35] Lo Gerfo P, Krupey J, Hansen HJ. Demonstration of an antigen common to several varieties of neoplasia[J]. N Engl J Med, 1971, 285(3): 138-141. [36] Borras G, Molina R, Xercavins J, et al. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix[J]. Gynecol Oncol, 1995, 57(2): 205-211. [37] Kjaer SK, Van Den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus(HPV)as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study[J]. BMJ, 2002, 325(7364): 572. [38] Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities[J]. J Natl Cancer Inst, 2005, 97(14): 1066-1071. [39] Walker JL, Wang SS, Schiffman M, et al. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study(ALTS)[J]. Am J Obstet Gynecol, 2006, 195(2): 341-348. [40] 桑勇先. CA125的研究进展[J]. 中国医药指南,2013,11(12): 451-453. [41] Liu L, Xu X, Jia L, et al. Primary fallopian tube carcinoma-a retrospective analysis of 66 cases[J]. Eur J Gynaecol Oncol, 2015, 36(2): 161-167. [42] Kalampokas E, Sofoudis C, Boutas I, et al. Primary fallopian tube carcinoma: a case report and mini-review of the literature[J]. Eur J Gynaecol Oncol, 2014, 35(5): 595-596. [43] Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use[J].Int J Gynecol Cancer, 2005, 15(5): 679-691. [44] Levy T, Weiser R, Boaz M, et al. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients[J]. Gynecol Oncol, 2013, 129(1): 165-168. [45] Papadimitriou CA, Markaki S, Lianos E, et al. Clinicopathological features of primary fallopian tube carcinoma: a single institution experience[J]. Eur J Gynaecol Oncol, 2009, 30(4): 389-395. [46] Rosen AC, Ausch C, Klein M, et al. p53 expression in fallopian tube carcinomas[J]. Cancer Lett, 2000, 156(1): 1-7. [47] Halon A, Rabczynski J. PCNA and laminin as prognostic factors in primary Fallopian tube carcinoma[J]. Folia Morphol, 2003, 62(4): 475-478. [48] Wang F, Sun GP, Zou YF, et al. Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features[J]. Folia Histochem Cytobiol, 2011, 49(3): 389-397. [49] Chhabra S, Bhavani MandDeshpande A. Trends of vulvar cancer[J]. J Obstet Gynaecol, 2014, 34(2): 165-168. [50] Del Pino M, Rodriguez-Carunchio LandOrdi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma[J]. Histopathology, 2013, 62(1): 161-175. |
| [1] | 王稳,董绍华,田翔宇,崔秀娟. 盆腹腔多发脾种植误诊为妇科肿瘤1例[J]. 山东大学学报 (医学版), 2020, 1(9): 116-118. |
| [2] | 曹冬焱,毕晓宁,沈铿. 抗苗勒氏管激素在妇科肿瘤领域的应用前景[J]. 山东大学学报 (医学版), 2018, 56(5): 8-12. |
| [3] | 李笑莹,刘芳,车海杰,张尽晖. 肿瘤标志物预测孤立性肺结节恶性概率模型的建立与初步评价[J]. 山东大学学报（医学版）, 2017, 55(4): 60-64. |
| [4] | 王晓花1，高淑春1，崔蕾2，蒋雪梅1，杜以真1. 白介素-28B在乙型肝炎病毒相关肝癌患者血清中的表达及意义[J]. 山东大学学报(医学版), 2012, 50(10): 106-110. |
| [5] | 上官红1，肖伟1，董亮1，李玉1，田辉2，郑天郢3. 血清CYFRA21-1、NSE和CEA在肺癌诊断和评估预后中的临床价值[J]. 山东大学学报(医学版), 2010, 48(12): 134-137. |
|
||
